# CD70

Source: https://onco.cc/targets/cd70/  
OnCo record `cd70` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias.

## Summary

CD70 is the TNF-family ligand for CD27, normally expressed only transiently on activated immune cells, but permanently switched on in clear-cell RCC and a range of haematologic malignancies with minimal normal expression. It is found in 80-90% of clear-cell RCC by IHC and on blasts and leukaemic stem cells in 30-50% of AML, as well as in lymphomas. Allogeneic CD70 CAR-T (ALLO-316) has shown responses in RCC, a notable result because solid tumours have resisted CAR-T. An advantage of the target is that CD70-directed cells may also deplete alloreactive host T cells, which helps off-the-shelf products persist. Durability of response and safety in AML are open. The simple version is an immune-cell protein that kidney cancer keeps switched on, offering a target for donor-derived CAR-T.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: car-t-target
- Symbol: CD70
- Class: surface-antigen
- Biology: CD70 is the TNF-family ligand for CD27.
- Where found: Clear-cell RCC; AML; Lymphomas

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CD70
- Wikipedia: https://en.wikipedia.org/wiki/CD70

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [ADI-270](https://onco.cc/drugs/adi-270/), [Cusatuzumab](https://onco.cc/drugs/cusatuzumab/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/)
- targets: [CD27](https://onco.cc/targets/cd27/)

---
JSON: https://onco.cc/api/v1/entities/cd70.json